In extremely severe cases, treatments that deaden the inner ear such as gentamicin injections or surgery may be considered. This is a last resort for persons who have severe attacks which are disabling. At present, we favor gentamicin for most instances where destructive treatments are being considered. Injections of gentamicin are given through the ear drum, through a small hole or through a small tube. This procedure allows the doctor to treat one side alone, without affecting the other. Typically, about four injections are given over a period of one month. Some authors have reported improvements in 60 to 90 percent of patients with gentamicin (Driscoll et al., 2009; Bodmer, 2007; Boleas-Aguirre, 2007; Chung, 2007), and Chung reported equally effective results with a single injection compared to multiple injections (Chung, 2007). Dizziness may reoccur one year later, requiring another series. Gentamicin injection can also result in hearing loss (Silvertein 2009; Colletti, 2007).
AB - Objective: To review published literature regarding the use of intratympanic steroids in the treatment of Ménière's disease and sudden sensorineural hearing loss and to make recommendations regarding their use based on the literature review. Data Sources: Literature review from 1996 to 2003, PubMed, Medline Plus, and Web of Science. Study Selection: Retrospective case series and uncontrolled prospective cohort studies were the only types of studies available for review. Conclusion: On the basis of the available literature, a weak recommendation is made to use intratympanic steroid treatment of sudden hearing loss if oral steroid therapy fails or is contraindicated. The available studies regarding intratympanic steroid treatment of Ménière's disease and tinnitus are inadequate to answer the question of the efficacy of this treatment for these conditions. Higher quality studies are needed.
As of July 2012, a visit to the National Library of Medicine’s search engine, PubMed, revealed 497 research articles concerning AIED disease published since 1964 with eleven of these published in the last year. In spite of this moderate effort by the medical research community, AIED disease remains a chronic, incurable disorder that causes progressive disability to both hearing and balance. At the American Hearing Research Foundation (AHRF) , we have funded basic research on similar disorders in the past , and are interested in funding research on AIED in the future. We are particularly interested in projects that might lead to methods of stopping progression of hearing loss and the disabling attacks of dizziness. Get more information about contributing to the AHRF’s efforts to detect and treat acoustic neuroma.